temozolomide has been researched along with fluorouracil in 50 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (2.00) | 18.2507 |
2000's | 14 (28.00) | 29.6817 |
2010's | 31 (62.00) | 24.3611 |
2020's | 4 (8.00) | 2.80 |
Authors | Studies |
---|---|
Lombardo, F; Obach, RS; Waters, NJ | 1 |
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
Benfenati, E; Raska, I; Toropov, AA; Toropova, AP | 1 |
Ekins, S; Williams, AJ; Xu, JJ | 1 |
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Liu, Y; Xu, Z; Zhao, SJ | 1 |
Brock, CS; Cunningham, VJ; Harte, RJ; Jones, T; Matthews, JC; Meikle, SR; Price, P; Wells, P | 1 |
Glickson, JD; Griffiths, JR | 1 |
Hoff, PM; Pazdur, R; Royce, ME | 1 |
Bonmassar, E; Graziani, G; Portarena, I; Tentori, L | 1 |
Baker, SD; Donehower, RC; Grochow, LB; Rowinsky, EK; Schellens, JH; Sparreboom, A; Verweij, J | 1 |
Aboagye, EO; Barthel, H; Collingridge, DR; Hutchinson, OC; Price, PM | 1 |
Bird, A; Bishop, SM; Clarke, AR; Guy, J; Sansom, OJ; Zabkiewicz, J | 1 |
Carminati, O; De Giorgi, U; Kopf, B; Marangolo, M; Rosti, G; Zago, S | 1 |
Kokkinakis, DM; Liu, X; Neuner, RD | 1 |
Arun, B; Broglio, K; Buchholz, T; Francis, D; Groves, M; Hortobagyi, GN; Meyers, C; Rivera, E; Valero, V; Yin, G | 1 |
Khan, MI; Kloecker, GH; Laber, DA; Salvador, C; Schonard, C; Taft, BS | 1 |
Chen, TC; Hofman, FM; Lee, AS; Pyrko, P; Schönthal, AH | 1 |
Baumgart, U; Bogdahn, U; Hau, P; Hirschmann, B; Kunz-Schughart, L; Muhleisen, H; Reichle, A; Ruemmele, P; Steinbrecher, A; Weimann, E | 1 |
Favaudon, V; Hennequin, C; Quero, L | 1 |
Bruce, JN; Fine, RL; Freda, PU; Isaacson, SR; Lee, Y; Thearle, MS | 1 |
Eriksson, B | 1 |
Bekele, BN; Bobustuc, GC; Colman, H; Conrad, CA; Gilbert, MR; Groves, MD; Hsu, SH; Levin, VA; Puduvalli, VK; Qiao, W; Walbert, T; Yung, WK | 1 |
Chen, DT; Choi, J; Coppola, D; Fine, RL; Helm, J; Kvols, L; Nasir, A; Strosberg, JR | 1 |
Busch, C; Knappskog, S; Oberg, K; Sebjornsen, S; Sorbye, H; Welin, S | 1 |
Borson-Chazot, F; Giraud, S; Joly, MO; Lombard-Bohas, C; Nozières, C; Riou, JP; Scoazec, JY; Simon, C; Walter, T | 1 |
He, F; Song, S; Tian, C; Wang, J; Wang, S; Xing, G; Yin, Y; Yuan, L; Zhang, L | 1 |
Claringbold, PG; Price, RA; Turner, JH | 1 |
Fine, RL; Gulati, AP; Krantz, B; Moss, RA; Mowatt, KB; Moyal, WN; Schreibman, S; Tsushima, DA | 1 |
Enk, AH; Gronau, M; Hassel, JC; Jäger, D | 1 |
Centeno, B; Kvols, L; Morse, B; Saranga-Perry, V; Strosberg, J | 1 |
Allendorf, J; Chabot, JA; Dinnen, RD; Fine, RL; Gulati, AP; Krantz, BA; Lee, JA; Mao, Y; Moss, RA; Mowatt, KB; Schreibman, S; Schrope, B; Sherman, WH; Stevens, PD; Tsushima, DA | 1 |
Costa, FP; Gumz, B; Pasche, B | 1 |
Brennan, M; Garcon, MC; Kaley, K; Rodriguez, G; Rodriguez, T; Saif, MW | 1 |
Bruce, JN; Carminucci, AS; Fine, RL; Gulati, AP; Lignelli, A; Remotti, H; Siegelin, M; Wardlaw, SL; Zacharia, BE | 1 |
Saif, MW; Tejani, MA | 1 |
Claringbold, PG; Kesavan, M; Turner, JH | 1 |
Cao, KI; Kirova, YM | 1 |
Sands, MJ; Wunderle, KA | 1 |
Abbasi, S; Albaba, H; Kashashna, A | 1 |
Backen, A; Barriuso, J; Elliott, E; Hubner, R; Lamarca, A; McNamara, MG; Valle, JW | 1 |
Budriene, S; Di Martino, A; Maciulyte, S; Pavelkova, A; Sedlarik, V | 1 |
Chen, J; Liu, Y; Ma, D; Mao, D | 1 |
Andreucci, E; Bianchini, F; Calorini, L; Carta, F; Laurenzana, A; Peppicelli, S; Ruzzolini, J; Supuran, CT | 1 |
Bai, CM; Cheng, YJ; Gao, X; Meng, CT; Yan, XY; Ying, HY; Zhou, JF; Zhou, N | 1 |
Barriuso, J; Hubner, RA; Lamarca, A; Manoharan, P; Mansoor, W; McNamara, MG; Valle, JW | 1 |
Antista, M; Barault, L; Corallo, S; de Braud, F; Di Bartolomeo, M; Di Maio, M; Di Nicolantonio, F; Farina, G; Fucà, G; Gori, S; Guarini, V; Lobefaro, R; Lonardi, S; Longarini, R; Macagno, M; Martinetti, A; Milione, M; Morano, F; Mosconi, S; Murgioni, S; Pagani, F; Palermo, F; Perrone, F; Petrelli, F; Pietrantonio, F; Raimondi, A; Randon, G; Rimassa, L; Sartore-Bianchi, A; Tamborini, E; Tomasello, G | 1 |
Al-Toubah, T; Morse, B; Pelle, E; Strosberg, J | 1 |
Dagohoy, CG; Dasari, A; Halperin, DM; Lam, M; Rogers, JE; Yao, JC | 1 |
11 review(s) available for temozolomide and fluorouracil
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1,2,3-Triazole-containing hybrids as potential anticancer agents: Current developments, action mechanisms and structure-activity relationships.
Topics: Antineoplastic Agents; Humans; Molecular Structure; Neoplasms; Structure-Activity Relationship; Triazoles | 2019 |
Monitoring pharmacokinetics of anticancer drugs: non-invasive investigation using magnetic resonance spectroscopy.
Topics: Antineoplastic Agents; Carbon Isotopes; Dacarbazine; Drug Monitoring; Fluorouracil; Humans; Magnetic Resonance Spectroscopy; Temozolomide | 2000 |
Novel oral chemotherapy agents.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Dacarbazine; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Neoplasms; Tegafur; Temozolomide; Uracil | 2000 |
Pharmacokinetics of radiolabelled anticancer drugs for positron emission tomography.
Topics: Acridines; Animals; Antineoplastic Agents; Dacarbazine; Fluorouracil; Humans; Molecular Structure; Radioactive Tracers; Radiopharmaceuticals; Temozolomide; Tissue Distribution; Tomography, Emission-Computed | 2003 |
[Biological basis of chemo-radiotherapy associations].
Topics: Cell Proliferation; Cisplatin; Combined Modality Therapy; Dacarbazine; Deoxycytidine; DNA Damage; DNA Repair; Fluorouracil; Gemcitabine; Humans; Neoplasms; Oxygen Consumption; Radiation Tolerance; Temozolomide | 2009 |
New drugs in neuroendocrine tumors: rising of new therapeutic philosophies?
Topics: Antineoplastic Agents; Capecitabine; Dacarbazine; Deoxycytidine; Drug Therapy; Everolimus; Fluorouracil; Humans; Indoles; Neuroendocrine Tumors; Octreotide; Pyrroles; Sirolimus; Sunitinib; Temozolomide; Treatment Outcome | 2010 |
Treatment of multiple endocrine neoplasia 1/2 tumors: case report and review of the literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Dacarbazine; Deoxycytidine; Fluorouracil; Humans; Male; Middle Aged; Multiple Endocrine Neoplasia Type 1; Multiple Endocrine Neoplasia Type 2a; Prognosis; Review Literature as Topic; Temozolomide; Tomography, X-Ray Computed | 2013 |
Selecting patients for cytotoxic therapies in gastroenteropancreatic neuroendocrine tumours.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cell Proliferation; Dacarbazine; Deoxycytidine; Fluorouracil; Humans; Intestinal Neoplasms; Neoplasm Grading; Neoplasm Staging; Neuroendocrine Tumors; Pancreatic Neoplasms; Patient Selection; Prognosis; Stomach Neoplasms; Streptozocin; Temozolomide | 2012 |
[Radiotherapy plus concomitant systemic therapies for patients with brain metastases from breast cancer].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials, Phase II as Topic; Dacarbazine; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Protein Kinase Inhibitors; Quinazolines; Radiotherapy, Adjuvant; Receptor, ErbB-2; Temozolomide; Thalidomide; Topoisomerase I Inhibitors; Topotecan; Trastuzumab; Vinblastine; Vinorelbine | 2014 |
Chemotherapy for advanced non-pancreatic well-differentiated neuroendocrine tumours of the gastrointestinal tract, a systematic review and meta-analysis: A lost cause?
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Dacarbazine; Disease-Free Survival; Fluorouracil; Gastrointestinal Neoplasms; Humans; Interferons; Neuroendocrine Tumors; Radiopharmaceuticals; Somatostatin; Streptozocin; Temozolomide | 2016 |
7 trial(s) available for temozolomide and fluorouracil
Article | Year |
---|---|
Phase I study of capecitabine in combination with temozolomide in the treatment of patients with brain metastases from breast carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Cohort Studies; Dacarbazine; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Fatigue; Female; Fluorouracil; Humans; Middle Aged; Nausea; Temozolomide; Treatment Outcome; Vomiting | 2006 |
A phase I study of thalidomide, capecitabine and temozolomide in advanced cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Combined Modality Therapy; Dacarbazine; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasms; Temozolomide; Thalidomide; Treatment Outcome | 2007 |
Low-dose chemotherapy in combination with COX-2 inhibitors and PPAR-gamma agonists in recurrent high-grade gliomas - a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain Neoplasms; Capecitabine; Cyclooxygenase 2 Inhibitors; Dacarbazine; Deoxycytidine; Drug Administration Schedule; Edema; Efferent Pathways; Erythema; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Glioblastoma; Glioma; Humans; Immunohistochemistry; Lactones; Male; Middle Aged; Neoplasm Recurrence, Local; Neovascularization, Pathologic; Pioglitazone; PPAR gamma; Predictive Value of Tests; Quality of Life; Sulfones; Temozolomide; Thiazolidinediones; Treatment Outcome | 2007 |
Phase I-II study of radiopeptide 177Lu-octreotate in combination with capecitabine and temozolomide in advanced low-grade neuroendocrine tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Combined Modality Therapy; Dacarbazine; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Male; Middle Aged; Neuroendocrine Tumors; Octreotide; Radiopharmaceuticals; Temozolomide; Treatment Outcome | 2012 |
Hematological toxicity of combined 177Lu-octreotate radiopeptide chemotherapy of gastroenteropancreatic neuroendocrine tumors in long-term follow-up.
Topics: Adult; Aged; Anemia; Antineoplastic Agents; Blood Platelets; Capecitabine; Dacarbazine; Deoxycytidine; Digestive System Neoplasms; Drug Therapy, Combination; Female; Fluorouracil; Follow-Up Studies; Hematologic Diseases; Humans; Incidence; Intestinal Neoplasms; Male; Middle Aged; Neuroendocrine Tumors; Neutrophils; Octreotide; Pancreatic Neoplasms; Radiopharmaceuticals; Randomized Controlled Trials as Topic; Stomach Neoplasms; Temozolomide; Thrombocytopenia; Treatment Outcome | 2014 |
Effect of Endostar combined with chemotherapy in advanced well-differentiated pancreatic neuroendocrine tumors.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Disease-Free Survival; Endostatins; Female; Fluorouracil; Humans; Induction Chemotherapy; Male; Middle Aged; Neuroendocrine Tumors; Pancreatic Neoplasms; Recombinant Proteins; Temozolomide; Treatment Outcome; Vascular Endothelial Growth Factor A | 2018 |
Capecitabine and Temozolomide versus FOLFIRI in RAS-Mutated, MGMT-Methylated Metastatic Colorectal Cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Camptothecin; Capecitabine; Colorectal Neoplasms; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Oxaliplatin; Proto-Oncogene Proteins p21(ras); Quality of Life; Survival Rate; Temozolomide; Treatment Outcome; Tumor Suppressor Proteins | 2020 |
32 other study(ies) available for temozolomide and fluorouracil
Article | Year |
---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
QSPR modeling of octanol/water partition coefficient of antineoplastic agents by balance of correlations.
Topics: Antineoplastic Agents; Models, Chemical; Octanols; Quantitative Structure-Activity Relationship; Water | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Pharmacokinetic assessment of novel anti-cancer drugs using spectral analysis and positron emission tomography: a feasibility study.
Topics: Acridines; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Colorectal Neoplasms; Dacarbazine; Feasibility Studies; Female; Fluorouracil; Glioma; Humans; Middle Aged; Spectrum Analysis; Temozolomide; Tomography, Emission-Computed | 1998 |
Combined effects of adenovirus-mediated wild-type p53 transduction, temozolomide and poly (ADP-ribose) polymerase inhibitor in mismatch repair deficient and non-proliferating tumor cells.
Topics: Adenoviridae; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Apoptosis; Base Pair Mismatch; Blotting, Western; Bromodeoxyuridine; Cell Division; Dacarbazine; DNA Repair; DNA Replication; Enzyme Inhibitors; Fluorouracil; Gene Deletion; Genetic Vectors; Humans; Jurkat Cells; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Protein Transport; Quinazolines; Temozolomide; Thiophenes; Transduction, Genetic; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2001 |
Role of body surface area in dosing of investigational anticancer agents in adults, 1991-2001.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Body Surface Area; Clinical Trials, Phase I as Topic; Cytosine; Dacarbazine; Dioxolanes; Docosahexaenoic Acids; Dose-Response Relationship, Drug; Drug Administration Schedule; Drugs, Investigational; Female; Fluorouracil; Humans; Infusions, Intravenous; Male; Paclitaxel; Retrospective Studies; Temozolomide; Uracil | 2002 |
MBD4 deficiency reduces the apoptotic response to DNA-damaging agents in the murine small intestine.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Survival; Cisplatin; Dacarbazine; DNA Damage; DNA Repair; Endodeoxyribonucleases; Fluorouracil; Intestinal Mucosa; Intestine, Small; Mice; Mice, Inbred C57BL; Mice, Inbred Strains; Mice, Knockout; Temozolomide | 2003 |
Innovative therapy for patients with brain metastases: oral treatments.
Topics: Administration, Oral; Brain Neoplasms; Capecitabine; Combined Modality Therapy; Dacarbazine; Deoxycytidine; Fluorouracil; Gefitinib; Humans; Quinazolines; Temozolomide | 2004 |
Modulation of cell cycle and gene expression in pancreatic tumor cell lines by methionine deprivation (methionine stress): implications to the therapy of pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Blotting, Western; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21; Dacarbazine; Fluorouracil; Gene Expression; Gene Expression Profiling; Humans; Methionine; Neoplasm Proteins; O(6)-Methylguanine-DNA Methyltransferase; Oligonucleotide Array Sequence Analysis; Pancreatic Neoplasms; Phosphorylation; Retinoblastoma Protein; Signal Transduction; Temozolomide; Transforming Growth Factor beta | 2005 |
The unfolded protein response regulator GRP78/BiP as a novel target for increasing chemosensitivity in malignant gliomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Caspase 7; Catechin; Cell Growth Processes; Cell Line, Tumor; Dacarbazine; Down-Regulation; Drug Screening Assays, Antitumor; Drug Synergism; Endoplasmic Reticulum Chaperone BiP; Fluorouracil; Glioblastoma; Heat-Shock Proteins; Humans; Irinotecan; Molecular Chaperones; RNA, Small Interfering; Temozolomide; Transcription Factor CHOP; Transfection | 2007 |
Temozolomide (Temodar®) and capecitabine (Xeloda®) treatment of an aggressive corticotroph pituitary tumor.
Topics: ACTH-Secreting Pituitary Adenoma; Adenoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Dacarbazine; Deoxycytidine; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Invasiveness; Radiography; Temozolomide; Treatment Outcome | 2011 |
Combination of 6-thioguanine, capecitabine, and celecoxib with temozolomide or lomustine for recurrent high-grade glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Capecitabine; Celecoxib; Dacarbazine; Deoxycytidine; Female; Fluorouracil; Glioblastoma; Gliosarcoma; Humans; Lomustine; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Prospective Studies; Pyrazoles; Sulfonamides; Survival Rate; Temozolomide; Thioguanine; Treatment Outcome; Young Adult | 2011 |
First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Islet Cell; Dacarbazine; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Retrospective Studies; Temozolomide; Tomography, X-Ray Computed | 2011 |
Clinical effect of temozolomide-based chemotherapy in poorly differentiated endocrine carcinoma after progression on first-line chemotherapy.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Capecitabine; Carcinoma, Neuroendocrine; Cisplatin; Dacarbazine; Deoxycytidine; Disease Progression; Disease-Free Survival; DNA Methylation; DNA Modification Methylases; DNA Repair; DNA Repair Enzymes; Drug Administration Schedule; Etoposide; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Promoter Regions, Genetic; Retrospective Studies; Salvage Therapy; Temozolomide; Treatment Outcome; Tumor Suppressor Proteins | 2011 |
A SDHB malignant paraganglioma with dramatic response to temozolomide-capecitabine.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Dacarbazine; Deoxycytidine; Drug Synergism; Fluorouracil; Humans; Immunohistochemistry; Male; Paraganglioma; Retroperitoneal Neoplasms; Succinate Dehydrogenase; Temozolomide; Treatment Outcome | 2012 |
N-methylpurine DNA glycosylase inhibits p53-mediated cell cycle arrest and coordinates with p53 to determine sensitivity to alkylating agents.
Topics: Antineoplastic Agents, Alkylating; Cell Cycle Checkpoints; Cell Cycle Proteins; Cell Survival; Comet Assay; Dacarbazine; DNA Breaks; DNA Glycosylases; DNA Repair; Drug Screening Assays, Antitumor; Fluorouracil; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; HCT116 Cells; Humans; MCF-7 Cells; Methyl Methanesulfonate; Nuclear Proteins; Point Mutation; Protein Binding; Protein Interaction Mapping; Protein Structure, Tertiary; Substrate Specificity; Temozolomide; Transcriptional Activation; Transfection; Tumor Suppressor Protein p53 | 2012 |
Necrolytic migratory erythema in a patient with neuroendocrine carcinoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Capecitabine; Carcinoma, Neuroendocrine; Dacarbazine; Deoxycytidine; Diagnosis, Differential; Drug Eruptions; Female; Fluorouracil; Follow-Up Studies; Humans; Immunohistochemistry; Necrolytic Migratory Erythema; Neoplasm Staging; Pancreatic Neoplasms; Paraneoplastic Syndromes; Risk Assessment; Temozolomide; Treatment Outcome | 2013 |
Treatment of metastatic neuroendocrine tumors of the thymus with capecitabine and temozolomide: a case series.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Dacarbazine; Deoxycytidine; Fluorouracil; Humans; Lymphatic Metastasis; Male; Mediastinal Neoplasms; Middle Aged; Neuroendocrine Tumors; Temozolomide; Thymus Neoplasms; Treatment Outcome | 2013 |
Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: The Pancreas Center at Columbia University experience.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Dacarbazine; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Liver Neoplasms; Male; Middle Aged; Neuroendocrine Tumors; Retrospective Studies; Survival Analysis; Temozolomide; Treatment Outcome | 2013 |
A retrospective study of capecitabine/temozolomide (CAPTEM) regimen in the treatment of metastatic pancreatic neuroendocrine tumors (pNETs) after failing previous therapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Dacarbazine; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Fatigue; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Neuroendocrine Tumors; Neutropenia; Pancreatic Neoplasms; Remission Induction; Retrospective Studies; Temozolomide; Thrombocytopenia; Time Factors; Treatment Outcome | 2013 |
High response rates and prolonged survival in patients with corticotroph pituitary tumors and refractory Cushing disease from capecitabine and temozolomide (CAPTEM): a case series.
Topics: ACTH-Secreting Pituitary Adenoma; Adenoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Dacarbazine; Deoxycytidine; Female; Fluorouracil; Humans; Immunohistochemistry; Male; Middle Aged; Pituitary ACTH Hypersecretion; Temozolomide | 2014 |
Pancreatic neuroendocrine tumors: does chemotherapy work?
Topics: Algorithms; Antineoplastic Agents; Capecitabine; Dacarbazine; Deoxycytidine; Drug Therapy; Drug Therapy, Combination; Fluorouracil; Humans; Neuroendocrine Tumors; Pancreatic Neoplasms; Temozolomide; Treatment Outcome | 2014 |
Radiation recall after a transarterial hepatic chemoembolization.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoid Tumor; Chemoembolization, Therapeutic; Dacarbazine; Deoxycytidine; Drug Administration Schedule; Fluoroscopy; Fluorouracil; Humans; Liver Neoplasms; Male; Middle Aged; Radiodermatitis; Radiography, Interventional; Risk Factors; Temozolomide; Time Factors | 2014 |
Efficacy of capecitabine and temozolomide combination in well-differentiated neuroendocrine tumors: Jordan experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoid Tumor; Cell Differentiation; Dacarbazine; Deoxycytidine; Developing Countries; Disease-Free Survival; Female; Fluorouracil; Gastrointestinal Neoplasms; Humans; Jordan; Male; Middle Aged; Neuroendocrine Tumors; Remission Induction; Retrospective Studies; Salvage Therapy; Temozolomide; Treatment Outcome | 2014 |
Polysaccharide-based nanocomplexes for co-encapsulation and controlled release of 5-Fluorouracil and Temozolomide.
Topics: Alginates; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Chitosan; Dacarbazine; Delayed-Action Preparations; Drug Carriers; Drug Combinations; Drug Compounding; Drug Liberation; Drug Stability; Fluorouracil; Glucuronic Acid; Hexuronic Acids; Nanoparticles; Pectins; Prodrugs; Temozolomide | 2016 |
Acyclic cucurbit[n]uril conjugated dextran for drug encapsulation and bioimaging.
Topics: Bridged-Ring Compounds; Dacarbazine; Dextrans; Drug Carriers; Ethylenediamines; Fluorouracil; HeLa Cells; Humans; Imidazoles; Luminescent Agents; Microscopy, Confocal; Nanoparticles; Particle Size; Polyethyleneimine; Temozolomide | 2017 |
The carbonic anhydrase IX inhibitor SLC-0111 sensitises cancer cells to conventional chemotherapy.
Topics: Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Carbonic Anhydrase Inhibitors; Carbonic Anhydrase IX; Cell Death; Cell Proliferation; Dacarbazine; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Fluorouracil; Gene Expression Regulation, Neoplastic; HCT116 Cells; Humans; MCF-7 Cells; Molecular Structure; Phenylurea Compounds; RNA, Messenger; Structure-Activity Relationship; Sulfonamides; Temozolomide; Tumor Cells, Cultured | 2019 |
Temozolomide-Capecitabine Chemotherapy for Neuroendocrine Neoplasms: The Dilemma of Treatment Duration.
Topics: Capecitabine; Duration of Therapy; Fluorouracil; Humans; Neuroendocrine Tumors; Temozolomide | 2020 |
Efficacy of FOLFOX in Patients with Aggressive Pancreatic Neuroendocrine Tumors After Prior Capecitabine/Temozolomide.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Fluorouracil; Humans; Leucovorin; Neuroendocrine Tumors; Oxaliplatin; Pancreatic Neoplasms; Retrospective Studies; Temozolomide; Treatment Outcome | 2021 |
Fluorouracil, Doxorubicin with Streptozocin and Subsequent Therapies in Pancreatic Neuroendocrine Tumors.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Everolimus; Female; Fluorouracil; Humans; Male; Middle Aged; Neuroendocrine Tumors; Pancreatic Neoplasms; Retrospective Studies; Streptozocin; Temozolomide; Treatment Outcome; Young Adult | 2022 |